Cytokinetics therapeutics
WebNov 28, 2006 · Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. WebAccord Healthcare, Inc., the US subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company headquartered in Durham, North Carolina. Through its …
Cytokinetics therapeutics
Did you know?
WebCytokinetics takes a purpose-driven approach by leveraging our unique muscle biology expertise to engineer compounds with specific characteristics aimed at treating diseases … WebCytokinetics Jan 2024 - Present 4 months. South San Francisco, California, United States Global Blood Therapeutics 1 year 8 months Senior Consultant, Clinical Outsourcing ...
WebApr 6, 2024 · Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is … WebCytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as …
WebMar 10, 2024 · Cytokinetics has an analyst consensus of Strong Buy, with a price target consensus of $61.31, a 56.7% upside from current levels. In a report issued on February 28, Raymond James also maintained... WebApr 11, 2024 · 12 analysts have issued twelve-month price targets for Cytokinetics' shares. Their CYTK share price forecasts range from $15.00 to $80.00. On average, they expect the company's stock price to reach $56.21 in the next year. This suggests a possible upside of 54.4% from the stock's current price. View analysts price targets for CYTK or view top ...
WebCytokinetics is dedicated to the discovery, development and commercialization of a novel class of therapeutics resulting from its leadership position in the emerging field of cytoskeletal pharmacology. Use the CB Insights Platform to explore Cytokinetics's full …
WebCytokine therapy has become commonplace. Some of these cytokines can produce significant bone marrow and peripheral blood changes in WBCs. The most commonly … dialysepraxis wuppertalWebNov 23, 2024 · Our commitment to cardiovascular disease remains steadfast, and we look forward to continuing to work closely with the cardiovascular community as we focus on advancing our innovative therapies, including our Lp (a) inhibitor olpasiran (AMG 890), which is currently in Phase 2," said David M. Reese, M.D., executive vice president of … dialysepraxis wolframstraßeWebDec 15, 2024 · Shares of Cytokinetics, Incorporated CYTK jumped 8.04% on Dec 14 even though the FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 8 to 3 that the benefits of omecamtiv mecarbil... cipher sysciphertek crossville tnWebMar 31, 2024 · Cytokinetics Muscle Biology Therapies Home empowering muscle empowering lives Cytokinetics is committed to our mission of developing potential medicines that may improve the healthspan of people living with cardiovascular and … Cytokinetics is a late-stage biopharmaceutical company focused on … Cytokinetics, Inc. does not by its reference above or distribution imply its … Cytokinetics is a late-stage biopharmaceutical company focused on … SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of … The key to muscle function is contraction. The principal functionality of muscle is … Heart failure affects 64 million people worldwide, hospitalizes more Americans … dialyse quakenbrück telefonnummerWebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential … dialysepraxis waltherstraße dresdenWebCytokinetics is a biopharmaceutical company developing therapies for debilitating diseases. South San Francisco, California, United States 251-500 Post-IPO Debt Public cytokinetics.com 1,449 Highlights Stock … ciphers with symbols